West Asia Crisis Squeezes India's Pharma Supply Chain: Who Gets Hurt and Who's Prepared

West Asia Crisis Squeezes India's Pharma Supply Chain: Who Gets Hurt and Who's Prepared

The escalating Israel-Iran conflict has created an unexpected casualty thousands of miles from the battlefield: India's pharmaceutical supply chain. As the government scrambles to secure methanol and key solvents used in life-saving drug manufacturing, the crisis is exposing a vulnerability that India's pharma giants have long warned about in their annual reports — heavy dependence on imported raw materials.

The Problem: Solvents and Feedstock Under Threat

India's pharma sector relies on petrochemical-derived solvents like ethyl alcohol, dimethylformamide (DMF), isopropyl alcohol, toluene, and methanol as essential inputs for API (Active Pharmaceutical Ingredient) manufacturing. Per Cohance Lifesciences' filings, raw material costs account for roughly 28-30% of revenue for CDMO and API manufacturers. When crude oil spikes and Middle Eastern supply routes are disrupted, these costs can surge rapidly.

The government has responded by exempting 40 petro products from customs duty for three months and entering talks with companies like Assam Petrochemicals to secure domestic methanol supply. But the question for investors is: which companies can absorb this shock, and which cannot?

Companies Facing Margin Pressure

Gland Pharma (GLAND) — As a pure-play injectable manufacturer operating a B2B model, Gland Pharma's gross profit margins have already been under pressure. Per their Q3 FY25 quarterly results, revenue stood at ₹15,452 million with a gross profit margin of 67%, but EBITDA margin was just 23%. Their filings note that the company focuses on "cost reduction" and "carefully reviewing contracts for pricing" — language that signals tight margin management. A solvent price spike could compress margins further for a company that procures APIs rather than manufacturing all of them in-house. Cohance Lifesciences (COHANCE) — This CDMO player reported Q3 FY25 revenue of ₹6,764 million with material margins of 71.5% and adjusted EBITDA margins of 39%. While these are healthy numbers, Cohance's filings acknowledge "significant concerns around the cost of manufacturing drugs on account of price rises." Their Q4 FY24 results showed how quickly margins can deteriorate — EBITDA margins fell from 51.7% to 34.2% in a single quarter when cost pressures intensified. The company's specialty chemicals CDMO segment (12% of revenue) is directly tied to petrochemical-derived inputs.

Companies Better Positioned

Cipla (CIPLA) — Among India's largest pharma companies, Cipla appears best prepared for supply chain disruptions. Per their FY25 annual report, the company achieved its highest-ever EBITDA margin of 25.9%, with revenue from its One India Business crossing ₹11,000 crore. Crucially, Cipla's risk management framework specifically addresses geopolitical volatility with concrete mitigation: "maintaining sufficient inventory balances for key strategic molecules," "prioritising alternate vendor development to de-risk single-source procurement," and replacing hazardous solvents with safer alternatives including water-based processes. Their five-year revenue CAGR of 17% suggests this isn't just talk — operational resilience is built into the business model. Sun Pharma (SUNPHARMA) — India's largest pharma company by market cap reported FY25 EBITDA growth of 17.3% with margins reaching 29%, up from 26.9% in FY24. Adjusted net profit rose 19% year-on-year. Sun Pharma's annual report describes its supply chain as subject to "dependence on supply chain for raw materials and active ingredients," but its sheer scale — ₹438.9 billion in FY24 consolidated revenue — gives it procurement leverage that smaller players lack. With 5% of revenue from its own API business, Sun Pharma has partial backward integration as a buffer. Mankind Pharma (MANKIND) — With 92% of its revenue coming from the domestic market, Mankind Pharma reported FY24 revenue of ₹10,335 crore with EBITDA margins expanding 280 basis points and PAT growing 48.2% year-on-year. The company's filing notes that EBITDA margin improvement was "driven by growth in Chronic [therapies] and stabilisation of API prices." This domestic-heavy revenue base means less exposure to currency fluctuations and export logistics disruptions, though input cost pressure remains a risk. Caplin Point Laboratories (CAPLIPOINT) — This mid-cap has been quietly building backward integration. Per their filings, the company acquired an API plant in Vizag as part of a backward integration strategy. Q3 FY25 revenue hit ₹493 crore with a gross profit margin of 60.4% and net profit margin of approximately 27%. Self-manufacturing APIs insulates Caplin from the worst of the solvent price surge, since vertically integrated companies can manage input sourcing more flexibly. Jubilant Pharmova (JUBLPHARMA) — Operating a state-of-the-art API manufacturing facility at Nanjangud spanning 41 acres with eight multi-stream manufacturing blocks, Jubilant's CDMO API business reported FY25 revenue of ₹5,811 million with EBITDA growing 39% to ₹874 million. The company has actively pursued "cost improvement and process innovation programs" for commercial APIs. Their own manufacturing capacity means they're a potential beneficiary if competitors who import APIs face shortages.

What Retail Investors Should Do

Don't panic-sell pharma stocks on West Asia headlines alone. Instead, check the filings:

1. Look at raw material costs as a percentage of revenue. Companies where materials are 30%+ of revenue (common in API/CDMO) face more margin risk than branded formulators where it's typically 25% or less.
2. Check for backward integration. Companies that manufacture their own APIs (Cipla, Caplin Point, Jubilant Pharmova) have a natural hedge.
3. Watch Q4 FY26 results closely. The solvent crunch impact will show up in the March quarter results — compare material cost ratios to the prior quarter.
4. Consider the government's response. The customs duty exemption on 40 petro products is a short-term cushion, and PLI scheme beneficiaries in API manufacturing stand to gain from the import substitution push.

The West Asia crisis is a stress test for pharma supply chains. Companies that talked about "de-risking" and "alternate vendor development" in their filings are about to prove whether those were real strategies or just risk-section boilerplate.

Data sourced from company filings on NSE via Xaro.